U.S. markets open in 5 hours 24 minutes
  • S&P Futures

    4,450.25
    -12.25 (-0.27%)
     
  • Dow Futures

    35,103.00
    -68.00 (-0.19%)
     
  • Nasdaq Futures

    15,067.50
    -67.00 (-0.44%)
     
  • Russell 2000 Futures

    2,254.30
    -10.70 (-0.47%)
     
  • Crude Oil

    83.23
    +0.95 (+1.15%)
     
  • Gold

    1,765.40
    -2.90 (-0.16%)
     
  • Silver

    23.39
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1600
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    17.40
    +0.54 (+3.20%)
     
  • GBP/USD

    1.3744
    +0.0067 (+0.49%)
     
  • USD/JPY

    114.2620
    +0.5850 (+0.51%)
     
  • BTC-USD

    62,015.44
    +1,591.82 (+2.63%)
     
  • CMC Crypto 200

    1,451.27
    +76.05 (+5.53%)
     
  • FTSE 100

    7,219.28
    -14.75 (-0.20%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug” that falls under section 505.

  • Related Content: Kaleido Reports Positive KB109 Data In COVID-19 Study.

  • Kaleido has 15 days to explain itself.

  • According to the letter, Kaleido was well aware of the FDA’s objections.

  • Regulators received a response, in which Kaleido argued that KB109, the synthetic glycan being tested in the study, was in fact “a food rather than a drug.”

  • Kaleido stated that subjects were instructed to follow CDC guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms and argued that KB109, therefore, was given for nutritional purposes and was not studied as a COVID-19 treatment.

  • The protocol, dubbed Protocol K031-120 and Protocol K032-120, and Kaleido’s press releases suggested otherwise, the FDA said.

  • Kaleido’s objective was to compare the safety and efficacy of KB109 in combination with supportive self-care against supportive self-care alone.

  • It also measured participants’ symptoms and healthcare utilization, like biomarkers and their gut microbiome structure.

  • The FDA wrote that the argument for describing KB109 as a medical food fails because no distinctive nutritional requirements have been established for COVID-19, which is a prerequisite for defining medical food.

  • Price Action: KLDO stock is down 5.19% at $6.03 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.